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Abstract 
Background: Disulfide bonds are the most common structural, post-translational modification found in proteins. 
Antibodies contain up to 25 disulfide bonds depending on type, with scFv fragments containing two disulfides 
and Fab fragments containing five or six disulfide bonds. The production of antibody fragments that contain native 
disulfide bonds can be challenging, especially on a large scale. The protein needs to be targeted to prokaryotic peri-
plasm or the eukaryotic endoplasmic reticulum. These compartments are specialised for disulfide bond formation, 
but both compartments have limitations.
Results: Here we show that the introduction into the cytoplasm of a catalyst of disulfide bond formation and a 
catalyst of disulfide bond isomerization allows the efficient formation of natively folded scFv and Fab antibody frag-
ments in the cytoplasm of Escherichia coli with intact reducing pathways. Eleven scFv and eleven Fab fragments were 
screened and ten of each were obtained in yields of >5 mg/L from deep-well plates. Production of eight of the scFv 
and all ten of the Fab showed a strong dependence on the addition of the folding factors. Yields of purified scFv of up 
to 240 mg/L and yields of purified Fab fragments of up to 42 mg/L were obtained. Purified fragments showed circular 
dichroism spectra consistent with being natively folded and were biologically active.
Conclusions: Our results show that the efficient production of soluble, biologically active scFv and Fab antibody 
fragments in the cytoplasm of E. coli is not only possible, but facile. The required components can be easily transferred 
between different E. coli strains.
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Background
Antibody fragments, in particular scFv and Fab frag-
ments (Fig. 1) have a wide range of uses in both academia 
and industry, including a critical role in diagnostics and 
an increasing role in therapeutics. While the recom-
binant production of full length antibodies is virtually 
exclusively performed in mammalian cell culture (for 
reviews see [1, 2]), in particular in Chinese hamster ovary 
(CHO) cells due to the requirement for post-translational 
modifications such as disulfide bond formation and 
N-glycosylation, a wider range of production platforms 
are used for scFv and Fab fragments which contain only 
disulfide bonds. These include production in the peri-
plasm of prokaryotes, such as Escherichia coli (for exam-
ple [3]), in the endoplasmic reticulum of eukaryotes 
including yeast, insect and mammalian cell culture (for 
examples [4, 5]) and in cell free expression systems (for 
example [6]). The lack of a clear frontrunner for a pro-
duction system for antibody fragments reflects the fact 
that all have advantages and disadvantages.
Production in E. coli has a number of advantages over 
other systems, including low cost, rapid growth, high bio-
mass, easily scalable cultivation and clear regulation for 
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therapeutic protein production. The primary disadvan-
tage of E. coli for antibody fragment production comes 
from the fact that production of the folded state can only 
occur in the periplasm as this is the only cellular com-
partment in E. coli in which catalysed formation of native 
disulfide bonds naturally occurs. The disadvantages of 
periplasmic production are twofold. Firstly the volume 
of the periplasm is much smaller than that of the cyto-
plasm, being typically cited as 8–16 % of the cell volume 
[7]. Secondly, the capacity secretion apparatus from the 
cytoplasm to the periplasm is easily overloaded, though 
this can be mitigated by reducing expression levels [8]. 
Both of these result in general lower levels of production 
of proteins in the periplasm compared with production 
in the cytoplasm.
To overcome these disadvantages we recently devel-
oped a system for the efficient production of disulfide 
bond containing proteins in the cytoplasm of E. coli, 
known as CyDisCo. CyDisCo is based on coexpression 
of a catalyst of disulfide bond formation, usually a sulf-
hydryl oxidase such as Erv1p [9, 10] but alternatively an 
inverted DsbB or VKOR [11], plus a catalyst of disulfide 
bond isomerization—either DsbC or PDI. CyDisCo has 
been used in house to produce more than 200 proteins, 
with the most optimal combination to date using Erv1p 
and PDI as the catalysts of native disulfide formation.
Here we addressed the question whether the CyDisCo 
system could be used to efficiently make scFv and Fab 
antibody fragments in the cytoplasm of E. coli. Spe-
cifically, we wanted to know whether this system was 
generic rather than specific i.e. if it would enable pro-
duction of a wide range of antibody types. Accord-
ingly we wished to have representatives of (i) different 
classes of antibodies (IgG1, IgG2, IgG4, IgA1, IgE and 
IgM were chosen); (ii) antibodies from different organ-
isms (human, mouse and humanized were chosen); (iii) 
representatives of well-known and widely used antibody 
drugs (Humira, Herceptin and Tysabri were chosen); 
(iv) representatives of antibodies that arose from Finn-
ish academia with potential use in diagnostics (Maa48, 
K2 and 3211 were chosen). Where possible we also 
wanted structural information on the antibodies to be 
available such that any differences observed in the effi-
ciency of production could potentially be linked back to 
differences in structure. The results indicated that more 
than 90 % of the scFv and Fab fragments tested could be 
produced in the cytoplasm and that they were correctly 
folded and biologically active.
Results and discussion
Systematic screening of antibody and antibody fragment 
production in the cytoplasm of E. coli
Antibodies contain a large number of disulfide bonds in 
their native state e.g. an IgG1 contains 19 disulfide bonds. 
However, they generally have a regular pattern with one 
intra-molecular disulfide per domain plus inter-molecu-
lar disulfide bonds which link the heavy and light chains 
together and the two heavy chains together. Exceptions 
to this pattern exist, for example in IgA and IgE there is 
an additional disulfide bond in the first constant domain 
of the heavy chain (Fig. 1). The low number of disulfide 
bonds suggests that it should be possible to make natively 
folded scFv (two disulfides) and Fab antibody frag-
ments (five disulfides, except IgA and IgE which have 
six disulfides) using CyDisCo in the cytoplasm of E. coli. 





































































Fig. 1 Schematic representation of antibodies fragments. Single chain (scFv) and Fab antibody fragments of types produced here are shown along 
with the position of the intra- and inter-molecular disulfide bonds
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the cytoplasm as they lack the consensus N-glycosylation 
sites found in the Fc region of antibodies.
We therefore decided to systematically screen the 
production of scFv and Fab antibody-fragments in the 
cytoplasm of E.coli using the CyDisCo system. Eleven 
antibodies were chosen for this screen, three human 
IgG1 (Humira; PDB structures  3WD5, 4NYL [12, 13]; 
Maa48 [14] and K2 [15]), two humanized IgG1 (Avas-
tin; PDB structures  1BJ1, 1CZ8 [16, 17] and Herceptin; 
PDB structures  1FVC, 1N8Z, 4HKZ [18–20]), a mouse 
IgG1 (3211; An anti-BNP antibody, Veijola, Vuolteenaho 
and Takkinen, unpublished observations), a mouse IgG2 
(PDB structure  1IGT [21]), a humanized IgG4 (Tysabri; 
PDB structure 4IRZ [22]), a human IgA1 (PDB structure: 
3M8O [23]), a human IgE (PDB structure: 2R56 [24]) and 
a human IgM (PDB structure: 1QLR [25]). Each of the 
11 scFv and Fab fragments derived from these antibod-
ies were expressed from otherwise identical vectors and 
expressed and purified under identical conditions i.e. 
not optimized for individual proteins, such that antibody 
specific differences could be observed.
Previously it has been reported that some antibody 
fragments can be expressed in ΔtrxB/Δgor strains of E. 
coli (for examples [26, 27]) in which the reducing path-
ways have been removed, but which have no active path-
ways for disulfide bond formation [28]. This suggests 
that some antibody fragments may require little or no 
assistance from catalysts of disulfide bond formation to 
reach a soluble state. To examine this possible effect all 
22 antibody constructs were expressed with and without 
CyDisCo components in 24 deep well plates using the 
KEIO collection parental K12 E. coli strain. This strain 
has the cytoplasmic disulfide bond reducing pathways 
intact. All expression tests were conducted at least in 
quadruplicate.
Examination of the soluble lysates by SDS-PAGE fol-
lowed by Coomassie staining allowed the direct visu-
alization of antibody fragment production in high yields 
for many of the constructs with CyDisCo present (data 
not shown). Since densitometric analysis of yields from 
lysates is prone to error e.g. due to co-migrating E.coli 
proteins, the 22 constructs expressed in the presence and 
absence of CyDisCo components were purified by IMAC 
from 3 mls of culture grown in 24 deep well plates. Since 
disulfide bond isomerization can occur in SDS if a free 
thiol group is present, the purified proteins were treated 
with N-ethylmalemide (NEM) to block free thiols before 
being analysed by reducing and non-reducing SDS–
PAGE. The results (Fig.  2; Table  1) indicate that 10 out 
of the 11 scFv and 10 out of the 11 Fab were expressed 
in sufficient yield to be visible in Coomassie stained gels 
(limit of detection circa 3  mg/L yield) when CyDisCo 
components were present. In contrast only two scFv, 
Herceptin and Tysabri, showed high-level CyDisCo inde-
pendent production and no Fab fragments were purified 
in the absence of CyDisCo.
All of the scFv produced were monomeric, with the 
exception of a very faint band of disulfide linked dimer 
for the Herceptin scFv present in some replicates. In 
contrast the Fab were predominantly a disulfide linked 
dimer of the heavy and light chains, though some mon-
omeric light and heavy chains i.e. not disulfide linked, 
could be observed e.g. for Herceptin and Tysabri. When 
small amounts of monomeric purified heavy and light 
chains were observed in the non-reducing gel analysis 
the apparent ratio was always 1:1 suggesting that dimers 
of the heavy and light chain were purified, but that some 
of these lacked the inter-chain disulfide bond and so ran 
as monomers on non-reducing SDS–PAGE.
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Fig. 2 Purification of antibodies and antibody fragments expressed 
in DWP in the cytoplasm of E. coli. Representative Coomasie stained 
non-reducing SDS-PAGE analysis of NEM treated IMAC purified 
antibody fragments in the cytoplasm of a K12 E. coli strain with (+) 
and without (−) expression of CyDisCo components Erv1p and PDI. 
Expression in 24 deep well plates, EnPressoB media at 30 °C. a scFv. 
The position of a Herceptin scFv disulfide linked dimer is marked 
with an arrow; b Fab. The position of the Fab dimer and light chain 
and heavy chain monomers are marked. In both panels the order 
is molecular weight markers (1) Humira (IgG1), (2) Maa48 (IgG1), (3) 
K2 (IgG1), (4) Avastin (IgG1 humanized), (5) Herceptin (IgG1 human-
ized), (6) 3211 (IgG1 mouse), (7) 1IGT (IgG2 mouse), (8) Tysabri (IgG4 
humanized), (9) 3M8O (IgA1), (10) 2R56 (IgE) and (11) 1QLR (IgM). All 
antibodies are human unless otherwise indicated. In both panels an 
E. coli protein which is occasionally seen co-eluting is marked with *. 
Treatment with NEM results in a slight smearing and laddering of the 
protein band. This is not seen in the absence of NEM (see Fig. 3a as an 
example)
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Shake flask scale production, purification and analysis 
of antibody fragments
Small scale production in 24 deep well plates (DWP) 
allowed preliminary screening of the production of anti-
body and antibody fragments, but it did not produce suf-
ficient protein for more detailed analysis. To examine in 
more detail the proteins produced using CyDisCo five 
scFv (Herceptin and Tysabri which showed CyDisCo 
independence, and 3211, 3M8O and 2R56 which showed 
CyDisCo dependence for production) and four Fab 
(Maa48, 3211, 3M8O and 1QLR) were chosen for pro-
duction in shake flasks. Based on the results from DWP 
expression, Herceptin and Tysabri scFv were produced 
with and without CyDisCo, while the other seven anti-
body fragments were produced only with CyDisCo pre-
sent to catalyse native disulfide bond formation. The 
proteins were purified by IMAC and the quality ana-
lysed by SDS–PAGE. Similar patterns were observed as 
observed in DWP expression (see Fig.  3a as example). 
The purified proteins were quantified using absorbance at 
280  nm (Table  2). While the yields of scFv were in line 
with estimates from SDS–PAGE of lysates, the yields of 
the Fab fragments were on average two-fold lower than 
expected, suggesting that the standard IMAC proto-
col or the placement of the hexahistidine tag at the end 
of the heavy chain was non-optimal. The yields in mg/L 
obtained for the nine antibody fragments tested in shake 
flask scale were on average 103  % of those obtained in 
DWP (compare Table  1 with Table  2) demonstrating 
the ease of going from screening scale to a scale suit-
able for structural or functional studies using CyDisCo in 
EnPresso B media.
To confirm that the proteins obtained were correctly 
folded far UV circular dichroism (CD) was performed. 
All of the proteins showed a CD spectra with a minima 
around 217  nm (Fig.  3b), consistent with the β-sheet 
found in the Ig fold.
To further confirm that the antibody fragments 
obtained were natively folded, a selection of them were 
tested for their ability to bind to their reported antigens. 
The scFv and Fab of 3211 bound to a peptide fragment 
of BNP, the antigen it was raised against (Fig. 3c). Due to 
the availability of suitable substrates, the binding speci-
ficity of the Fab fragment of Maa48 was analysed in more 
detail. Maa48 Fab bound to malondialdehyde-acetalde-
hyde (MAA)-modified antigen, but not to malondialde-
hyde (MDA)-modified antigen or to the non-modified 
antigen (Fig. 3d, e). In addition, Maa48 Fab did not bind 
to copper oxidized LDL or carbamylated LDL. These 
results match the published specificity of Maa48 (also 
known as Fab-pre; [14]) and imply that antibody frag-
ments produced using CyDisCo in the cytoplasm of E. 
coli retain biological activity and specificity.
Analysis of Herceptin and Tysabri scFv
Both Herceptin and Tysabri were unusual in that the 
scFv were solubly expressed in high yields in the absence 
of CyDisCo components i.e. under conditions in which 
disulfide bond formation should not occur. While the puri-
fied yields in the absence of CyDisCo were up to one-third 
lower of that obtained in the presence of CyDisCo compo-
nents, the high level produced suggests either that the pro-
teins are soluble and proteolytically stable in the absence of 
disulfide bond formation or that disufide bond formation 
occurs via an alternative route for these scFv. To examine 
the redox state of these the IMAC purified scFv produced 
in the presence and absence of CyDisCo were analysed.
Herceptin scFv produced using CyDisCo showed a 
small mobility shift in SDS–PAGE in the presence and 
absence of β-mercaptoethanol (data not shown), indicat-
ing that it contained at least one intra-molecular disulfide 
bond. In contrast the same scFv produced in the absence 
of CyDisCo showed no mobility shift. The absence of 
disulfide bonds in both Herceptin and Tysabri scFv when 
produced in the absence of CyDisCo was confirmed by 
electrospray mass spectrometry (Table 3). Similarly both 
scFv were confirmed to contain two disulfide bonds when 
made in the presence of CyDisCo.
Conclusions
By using the CyDisCo system for disulfide bond forma-
tion we were able to generate high yields of folded, bio-
logically active, antibody fragments (scFv and Fab) in 
the cytoplasm of E. coli with a >90  % success rate. The 
direct, systematic, side by side comparison of eleven dif-
ferent antibodies of eight different types with no pro-
tein dependent optimization demonstrates the flexibility 
of the system. The use of CyDisCo for the production 
Table 1 Average yields of  purified antibody fragments 
from DWP cultures
Yields were determined by densitometric analysis using yields of purified scFv 
and Fab from shake flasks as calibration controls
Antibody name Type scFv (mg/L) Fab (mg/L)
Humira IgG1 human 33 5
Maa48 IgG1 human 4 43
K2 IgG1 human 11 26
Avastin IgG1 humanized – 3
Herceptin IgG1 humanized 271 50
Tysabri IgG4 humanized 139 25
3211 IgG1 mouse 19 9
Mab123 IgG2 mouse 6 42
3M8O IgA1 human 86 17
2R56 IgE human 32 –
1QLR IgM human 26 9
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of proteins containing up to nine disulfide bonds [10], 
suggests that it could also be used to produce antibody 
fragments with engineered disulfide bonds to increase 
stability [29].
Of the 22 constructs tested only two, the scFv of Her-
ceptin and Tysabri, were produced in a soluble state 
in the absence of CyDisCo, the rest being produced as 
inclusion bodies. Sequence analysis of the eleven scFv 
(see Additional file 1 for an alignment) showed no con-
sensus in sequence either at a global or at a local level to 
explain why these two alone were able to fold to a soluble 
stable state in the absence of disulfide bond formation. 
Similarly no consensus was observed when comparing 
the available structures of the variable domains of these 
two antibodies in comparison with those antibodies 
whose scFv were only produced in a soluble state when 
CyDisCo components were present.
In vitro studies of antibody folding strongly suggest the 
involvement of multiple protein folding factors beyond 
those catalysing disulfide bond formation (reviewed in 
[30, 31]). In particular cis-prolyl isomerization is a rate 
limiting step that requires the action of a peptidyl prolyl 
cis–trans isomerase (PPI) and the first constant domain 
of the heavy chain (CH1) requires the action of the molec-
ular chaperone BiP, a HSP70 family member, to retain 
it in a folding competent state until the heavy and light 
chain associate. Our system adds neither of these factors 
and yet yields of purified protein of up to 250  mg/L of 
Fig. 3 Analysis of antibody fragments produced using CyDisCo in the cytoplasm of E. coli grown in shake flasks. a Coomassie stained non-reducing 
SDS-PAGE analysis of IMAC purified 3211 (IgG1 mouse) scFv (lane 1) and Fab (lane 2) antibody fragments. b Far UV circular dichroism spectra of IMAC 
purified 3211 scFv and Fab fragments. c 3211 scFv and Fab binding to recombinant NTproBNP1-76; d Maa48 Fab binding to native and modified 
LDL; e Maa48 Fab binding to native and modified BSA
Table 2 Yields of antibody fragments purified from shake 
flask cultures
Yields were determined by A280 measurements. Extinction coefficients used 
were calculated using ProtParam and assuming all of the cysteines present are in 
disulfide bonds. Except where stated all fragments were made in the presence of 
CyDisCo components
Fragment type Antibody name Purified yield
scFv Herceptin (human IgG1) 251 mg/L (with CyDisCo)
167 mg/L (without CyDisCo)
Tysabri (human IgG4) 169 mg/L (with CyDisCo)
141 mg/L (without CyDisCo)
3211 (mouse IgG1) 11 mg/L
3M8O (human IgA1) 68 mg/L
2R56 (human IgE) 32 mg/L
Fab Maa48 (human IgG1) 42 mg/L
3211 (mouse IgG1) 13 mg/L
3M8O (human IgA1) 19 mg/L
1QLR (human IgM) 11 mg/L
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folded scFv and 42 mg/L of folded Fab are obtained from 
shake flasks without protein specific optimization. This 
suggests that intrinsic E. coli proteins fulfil these roles. 
E. coli has six cytoplasmic PPIs (the gene products of 
fkpB, fkbX, ppiB, ppiC, slyD and tig) and one cytoplasmic 
HSP70 family member (the gene product of dnaK) and 
the most probably explanation is that these fulfil the roles 
necessary for antibody fragment folding. Only the cata-
lysts of native disulfide bond formation need to be added.
The production levels of the scFv and Fab obtained 
varied by circa 60-fold for the 10 scFv and nearly 20-fold 
for the 10 Fab produced. No patterns were observed 
based on antibody subtype—for example the best pro-
duced scFv were IgG1 and IgG4 subtypes, while the best 
and worse Fab were both IgG1 subtypes. In addition, no 
patterns were observed based on sequence analysis (see 
Additional file  1: Figures S1 and S2) or on structural 
analysis—based on the available structures for eight of 
the antibody fragments. In general the levels of Fabs were 
lower than those of scFv (23 mg/L on average compared 
with. 63 mg/L on average, but note the bias caused by the 
two scFv which do not have a requirement for CyDisCo). 
However, there was no simple correlation between the 
production levels of the scFv and that of the correspond-
ing Fab, even within a single antibody subtype. This is 
neatly exemplified by Humira and Maa48, both human 
IgG1 subtypes, with the yields from DWP of the Fab com-
pared with the scFv being circa 6× lower for Humira, but 
circa 10× higher for Maa48 (Table 1).
As we wanted to have a systematic side-by-side com-
parison of the abilities of the system, no systematic pro-
tein specific optimization was performed. As such this 
makes direct comparison with published data for other 
production systems problematic as usually protein 
specific optimization is performed as there only one or 
two target proteins rather than, as here, a wider ranging 
proof of concept for a class of proteins. Other systems, 
such as expression in the endoplasmic reticulum of 
CHO or yeast or periplasmic expression in E. coli have 
achieved yields in excess of 1  g/L for antibodies and/or 
antibody fragments after optimization. Preliminary data 
using CyDisCo suggests that with optimization higher 
yields may be obtained, with an increase in yield of at 
least twofold having already been obtained for more than 
half of the 22 constructs tested here. For example yields 
of more than 150  mg/L of Maa48 Fab and more than 
100  mg/L of 2R56 scFv have been obtained from DWP 
expression during preliminary optimization. As per any 
heterologous protein expression such optimization may 
need to include choice of vector, codon usage, transla-
tion initiation, mRNA stability, relative expression levels 
of subunits in multi-subunit complexes, bacterial strain, 
media and expression, induction and purification con-
ditions, etc. Further studies aimed towards increasing 
yields and being able to make sequence based predictions 
of yields are ongoing. However, preliminary data from 
these antibody fragments, combined with data from suc-
cessful expression of more than 100 other proteins using 
CyDisCo, within our research group suggests that one of 
two effects may be limiting yields for specific antibody 
fragments: (1) proteolytic stability i.e. that the protein 
is made, folds, but the folded state is prone to proteoly-
sis by cytoplasmic proteases; (2) solubility of the fold-
ing intermediates or, less commonly, of the final folded 
state. While the solubility of the final native state can be 
readily determined, or to some extent predicted based 
on sequence, the solubility of folding intermediates is 
currently unpredictable. However, testing a wider range 
of scFv to identify more examples like Herceptin and 
Tysabri derived scFv which are able to reach a stable, sol-
uble state in the absence of disulfide bond formation may 
allow further elucidation of factors which increase the 
solubility of folding intermediates of antibody fragments 
and hence increase yields. Such data may also impact on 
yields obtained in other production systems. To date no 
patterns have been identified to allow prediction of which 
factors require optimization for any given protein, except 
that disruption of the reducing pathways e.g. the use of 
a ΔtrxB/Δgor strain such as rosetta-gami, combined with 
CyDisCo components expressed at high levels (such as 
from the plasmid used here) is usually deleterious to the 
production of native disulfide bonds. This effect prob-
ably arises as the system becomes over-oxidizing and is 
unable to catalyse isomerization of non-native disulfides 
to the native state.
To date CyDisCo works in all E. coli strains tested and 
in all media tested, including minimal media in batch or 
Table 3 Molecular mass of  scFv fragments produced 
with and without CyDisCo
Masses were determined by electrospray mass spectrometry with (+) or without 
(−) prior treatment with N-ethylmaleimide (NEM) which reacts with free thiol 
groups. Reaction with NEM increases the mass of the protein by 125 Da. In the 
absence of CyDisCo a 500 Da shift in mass was observed upon NEM treatment 
consistent with four free thiol groups i.e. no disulfide bonds. In contrast in 
the presence of CyDisCo no shift in mass was observed upon NEM treatment 
consistent with both disulfide bonds being formed
scFv CyDisCo NEM treatment Molecular mass (Da)
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batch-fed fermentation (manuscript in preparation) and 
no deleterious effects have been observed of CyDisCo 
component expression in production strains in any 
media tested. Hence, despite the requirement for further 
optimization and scale up our results opens up a wide 
range of possibilities for the production of therapeutic 




Expression vectors (see Table  4 for vectors used in 
this study) were made by standard molecular biology 
techniques.
Genes for the Erv1p, mature PDI along with the heavy 
and light chains of the antibodies tested (lacking the 
N-terminal signal sequence) were synthesized codon 
optimized for E .coli expression (GenScript; Additional 
file  1: Figure S3). IgE and IgM heavy chains were syn-
thesized without the C-terminal region involved in 
oligomerization.
The expression vector used was a modified version of 
pET23 in which the T7 promoter was replaced with Ptac 
promoter from previously modified (SpeI site inserted) 
pMal-p2X [10] by digesting the pMal-p2X with MscI/
SpeI and ligating the fragment into MscI/XbaI digested 
pET23. Synthetic multi-cloning sites for Fab fragments 
(EcoRV/XhoI) and scFv fragments (EcoRV/CelII) were 
synthesised (GenScript) and ligated into this vector 
backbone.
The variable domains of the light and heavy chain were 
amplified by PCR from the synthetic genes and cloned 
into a synthetic multi-cloning site using NdeI/KasI (light 
chain) and XhoI/BamHI (heavy chain) to generate a scFv 
with a C-terminal hexahistidine-tag (Fig.  4). Since the 
vector backbone, tag and linker region were constant any 
differences in scFv production comes from the variable 
regions.
The truncated heavy chain for Fab production was 
amplified by PCR from the synthetic gene and cloned 
XbaI/BamHI into a polycistronic vector with the light 
chain (cloned NdeI/Hind III). These polycistronic vectors 
include two ribosome binding sites (rbs) and make two 
proteins by co-expression from two translation initiation 
sites (Fig. 4). All heavy chain fragments included a C-ter-
minal hexahistidine-tag. The tag was placed on the heavy 
chain rather than the light chain as preliminary studies 
on other Fab fragments had suggested that in some cases 
soluble light chain could be generated and purified in the 
absence of heavy chain co-expression whereas the oppo-
site was not observed i.e. having the tag on the heavy chain 
was designed to increase the quality of the final product.
A polycistronic expression construct for codon opti-
mized Erv1p and codon optimized mature PDI was made 
in modified pET23 as described previously [9]. The poly-
cistronic fragment was transferred into the new vector 
with Ptac promoter by cloning XbaI/XhoI. From there 
the fragment containing Ptac promoter, codon optimized 
Erv1p and codon optimized PDI was cloned NsiI/AvrII 
into modified a pLysSBAD-vector described previously 
[10] to generate pMJS205 expression vector. A control 
construct identical to pMJS205, except lacking the genes 
for Erv1p and PDI was made by removing the genes by 
NdeI/SpeI digestion and ligating in short annealed prim-
ers with complementary sticky ends.
All plasmid purification was performed using the Gen-
Elute HP Plasmid Miniprep Kit (Sigma Aldrich) and all 
purification from agarose gels was performed using the 
Gel/PCR DNA Fragments Extraction Kit GeneAid), both 
according to the manufacturers’ instructions.
Table 4 Details of the plasmid vectors used in this study
Name Type scFv Fab
Humira IgG1 human pJV77 pJV59
Maa48 IgG1 human pJV79 pJV11
K2 IgG1 human pJV80 pJV12
Avastin IgG1 humanized pJV76 pYU177
Herceptin IgG1 humanized pJV78 pJV60
Tysabri IgG4 humanized pJV81 pJV61
3211 IgG1 mouse pJV82 pJV13
Mab123 IgG2 mouse pJV83 pYU183
3M8O IgA1 human pJV84 pJV62
2R56 IgE human pJV85 pJV63
1QLR IgM human pJV86 pJV64
CyDisCo components Erv1p + PDI pMJS205
CyDisCo negative control None pAG82
rbs
NdeI                      KasI XhoI                     BamHI
His-tag Spacer
rbs




Heavy chain Light chain
VL domain VH domain
Fig. 4 Structure of the expression vectors used in this study. a scFv 
vector. The spacer region including the KasI and XhoI sites encodes 
for the sequence -Gly-Ala-Ser-(Gly4-Ser)3-Ser- while the hexahistidine-
tag including the BamHI site adds Gly-Ser-His6. rbs = ribsome binding 
site. The initiating Met is included in the NdeI site (CATATG); b Fab 
vector. This polycistronic vector includes two ribosome binding 
sites (rbs) to initiate translation of the heavy and light chain. The 
hexahistdine-tag including the BamHI site adds Gly-Ser-His6
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All plasmids generated were sequenced to ensure there 
were no errors in the cloned genes.
Protein expression
For expression in EnPresso B media in 24 deep well 
plates, E. coli strains containing expression vectors were 
streaked out from glycerol stocks stored at −70 °C onto 
LB agar plates containing 5 g/L glucose and suitable anti-
biotics to allow for selection (100  μg/ml ampicillin for 
pET23 derivatives, 35  μg/ml chloramphenicol for pLysS 
derivatives) and the plates incubated at 37 °C overnight. 
The next day one–three colonies from these plates were 
used to inoculate 2  ml of LB media supplemented with 
2 g/L glucose, containing suitable antibiotics, and the cul-
tures grown at 30 °C, 200 rpm (2.5 cm radius of gyration) 
in 24 deep well plates covered with an oxygen permeable 
membrane for 6–8  h. These cultures were used to seed 
24 deep well plates containing 3 mls of EnPresso B media 
(Biosilta Oy; as manufacturer’s instructions) per well 
containing suitable antibiotics and the cultures grown at 
30 °C, 200 rpm (5 cm radius of gyration) in 24 deep well 
plates covered with an oxygen permeable membrane for 
approximately 16 h. The cultures were then boosted (as 
manufacturer’s instructions) and induced with 0.5  mM 
IPTG. Cultures were harvested after a further 24  h of 
growth. Final OD600 values of the cultures were in the 
range 20–37. The cells were collected by centrifugation 
and resuspended in 3  mls of 50  mM sodium phosphate 
pH 7.4, 20 μg/ml DNase, 0.1 mg/ml egg white lysozyme. 
After 10  min incubation the resuspended cultures were 
frozen. Cells were lysed by freeze-thawing.
Protein expression in shake flasks was as per 24 deep 
well plates except the media volume was 25 mls (250 ml 
flask) of EnPresso B media and cultures were grown at 
30 °C, 250 rpm (2.5 cm radius of gyration). Resuspension 
was done in the same volume as the initial culture.
Protein purification and analysis
Purification of hexa-histidine tagged proteins was per-
formed by standard immobilized metal affinity chro-
matography using HisPur Cobalt Superflow Agarose 
(Thermos Scientific) resin under native conditions fol-
lowing clearance of the cell lysate by centrifugation 
(4000  rpm, 20  min, 4  °C) for 24 deep well plate. For 
3  ml cultures from 24 deep well plates IMAC was per-
formed using 0.5 ml resin in small gravity feed columns. 
The resin was washed with 2  ×  5  mls of water, equili-
brated with 2 ×  5  mls of 50  mM phosphate buffer (pH 
7.4). After loading the sample the column was equili-
brated with 5  ml of 50  mM phosphate buffer (pH 7.4), 
washed with 4 ×  5  mls of wash buffer (50  mM sodium 
phosphate, 5 mM imidazole, 0.3 M sodium chloride; pH 
7.4) then 5  mls of 50  mM sodium phosphate (pH 7.4) 
before elution with 3 × 0.7 mls of 50 mM sodium phos-
phate, 150  mM imidazole (pH 7.4). For 25  ml cultures 
the same protocol was used with the following changes: 
1.0  ml of resin; 6  ×  5  mls of wash buffer; elution with 
4 × 1 ml of buffer. Where needed, 2.5 ml of eluted sam-
ple was desalted into 50 mM sodium phosphate (pH 7.4) 
on PD-10 columns (GE Healthcare). Appropriate samples 
were treated with 20 mM NEM for 20 min at room tem-
perature prior to making SDS–PAGE samples or mass 
spectrometry analysis.
Protein analysis
Far-UV circular dichroism spectra were recorded on a 
Chirascan- plus CD spectrophotometer. All scans were 
collected at 25 °C as an average of four scans, using a cell 
with a path length of 0.1 cm, scan speed 2 nm/s, step size 
0.5  nm, a spectral band width of 1.0  nm. The maximal 
HT voltage was 750 V.
For determining binding of 3211 Fab and scFv to their 
ligand, 100  ng of recombinant NTproBNP1-76 [32] in 
0.1 M sodium bicarbonate buffer pH 9.6 was coated per 
well on a shaking ELISA plate over-night at 4  °C. The 
wells were emptied and rinsed three times with 250 μl of 
1xPBS (20 mM phosphate, 150 mM sodium chloride, pH 
7.4) containing 0.05  %v/v tween 20 and then incubated 
with 250 μl of blocking buffer (0.2 % gelatin, 0.5 % BSA, 
0.05 % v/v tween20 in 1xPBS, pH 7.4) for 20 min at room 
temperature. Then 100 μl samples containing 0–20 ng of 
scFv or Fab, diluted in the blocking buffer were incubated 
for 2  h at room temperature shaking. After removal of 
the sample and washing the wells six times with 300 μl of 
1xPBS containing 0.05 % v/v tween 20, 100 μl of alkaline 
phosphatase labelled anti-HIS antibody (Sigma) diluted 
1:10000 in blocking buffer was added and the reactions 
incubated for 1 h at room temperature. After removal of 
the detection antibody and washing the wells six times 
with 300  μl of 1xPBS containing 0.05  % tween 20, the 
1 mg/ml pNPP-substrate solution (Sigma) in 0.2 M Tris, 
5  mM MgCl2 was added and incubated for 30  min at 
room temperature. The absorbance at 405 nm was meas-
ured with a Tecan Infinite M1000PRO multilabel reader.
For determining the specificity of Maa48 Fab binding, 
the ligand (MAA-LDL, MDA-LDL, copper oxidized-
LDL, carbamylated-LDL, native LDL, MAA-BSA, MDA-
BSA or native BSA; sources) at 0–20 μg/ml concentration 
in PBS was bound to an ELISA plate at 4  °C overnight. 
The antigens were prepared as described [15]. The plate 
was washed three times with 0.27  mM EDTA in PBS 
using an automated plate washer. Nonspecific binding 
was blocked with 0.5 % fish gelatin and 0.27 mM EDTA 
in PBS for 1  h at room temperature. Maa48 Fab (1  µg/
ml) was incubated for 1 h at room temperature. Alkaline 
phosphatase-conjugated anti-human IgG (Fab) (Sigma) 
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was used as a secondary antibody and LumiPhos 530 
(Lumigen) as a substrate in the assay [14]. The chemilu-
minescence was measured as relative light units (RLU) 
with a Wallac Victor3 multilabel reader (Perkin Elmer).
Masses of purified and desalted proteins, treated and 
not treated with 20 mM NEM were measured by LCMS 
with an Aquity UPLC-system (Waters) connected to a 
Synapt G1 Q-ToF –type mass spectrometer. The analyti-
cal column was a BEH 300 C4, 2.1 ×100  mm (Waters) 
run at 0.4  ml/min using a gradient from 3  % acetoni-
trile in water/0.1 % formic acid to 70 % acetonitrile over 
15 min. Samples were acidified with trifluoracetic acid to 
about 0.5 % v/v and 5 µl of the sample was injected. The 
mass spectrometer was operated in sensitivity mode with 
lock mass corrected 1  s scans in continuous mode for 
m/z 400–2000. Capillary voltage was 3.5 kV, cone voltage 
30 V. Mass spectra were base line subtracted and decon-
voluted with MaxEnt1.
Abbreviations
DWP: deep well plate; NEM: N-ethyl maleimide; PDI: protein disulfide 
isomerase.
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